Methods comprising apoptosis inhibitors for the generation of transgenic pigs |
 |
|
|
||||||||||||||||||||||||||||||||||||||||||
| Title: | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| Inventors: | Bennett, Brian D.; Pacifica, CA, USA Broz, SUSA n D.; San Bruno, CA, USA Matthews, William; Woodside, CA, USA Zeigler, Francis C.; San Mateo, CA, USA |
| Summary: | This invention describes agonist antibodies which bind to the extracellular domain of the flk2/flt3 receptor and thereby activate the intracellular kinase domain. The labeled antibodies are useful as diagnostics for detecting the presence of the flk2/flt3 receptor in primitive hematopoietic cells, and the antibodies are able to cause primitive hematopoietic cells to proliferate and/or to differentiate and thereby enhance repopulation of mature blood cell lineages in a mammal which has undergone chemo- or radiation therapy or bone marrow transplantation. The antibodies are further useful for treating mammals which have suffered a decrease in blood cells as a consequence of disease or a hemorrhage, among other disorders. |
| Abstract: | Agonist antibodies are disclosed which bind to the extracellular domain of the flk2/flt3 receptor and thereby activate the intracellular kinase domain thereof. The labeled antibodies are useful as diagnostics for detecting the presence of the flk2/flt3 receptor in primitive hematopoietic cells for example. The antibodies are able to cause primitive hematopoietic cells to proliferate and/or differentiate and thereby enhance repopulation of mature blood cell lineages in a mammal which has undergone chemo- or radiation therapy or bone marrow transplantation. The antibodies are further useful for treating mammals which have suffered a decrease in blood cells as a consequence of disease or a hemorrhage, for example. |
| US Patent Website: | Click Here for Full Text of Patent |
| Title Number: | US5635388 |
| Application Number: | US1994000222299 |
| Date Filed: | 04/04/1994 |
| Date Published: | 03/06/1997 |
| Assignee: | Genentech, Inc., South San Francisco, CA, USA |